Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].
Ann Oncol
; 35(5): 482, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38195363
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article